| Project/Area Number |
12470141
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
ABE Koji Okayama University, Graduate School of Medicine and Dentistry, Professor, 大学院・医歯学総合研究科, 教授 (20212540)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAGANO Isao Okayama University, Hospital, Lecturer, 医学部附属病院, 講師 (80335603)
SHOJI Mikio Okayama University, Graduate School of Medicine and Dentistry, Associate Professor, 大学院・医歯学総合研究科, 助教授 (60171021)
真邊 泰宏 岡山大学, 医学部・附属病院, 講師 (30325112)
割田 仁 岡山大学, 医学部・附属病院, 助手 (60325115)
柏原 健一 岡山大学, 医学部・附属病院, 講師 (80204387)
|
|---|
| Project Period (FY) |
2000 – 2002
|
| Project Status |
Completed (Fiscal Year 2002)
|
| Budget Amount *help |
¥12,200,000 (Direct Cost: ¥12,200,000)
Fiscal Year 2002: ¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 2001: ¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2000: ¥6,100,000 (Direct Cost: ¥6,100,000)
|
|---|
| Keywords | ALS / SOD1 / transgenic mice / IGF-1 / SOD / 遺伝子治療 |
|---|
| Research Abstract |
With transgenic mice of mutant SOD1, survival signals such as PI3K, Akt, bcl2 were found to be decreased from early period of presymptomatic stage. VEGF induction after hypox is was greatly reduced in this transgenic mice model. Furthermore, reduction of glutamatergic AMPA receptor is also involved in the pathogenesis of the disease.
For development of in vivo treatment for ALS, intrathecal injection of IGF-1 was newly developed for experimental mice and human patients. With this therapy, motor neurons were well preserved with retention of survival signals. Furthermore, intrathecal injection of IGF-1 also preserved clinical symptoms. of human ALS patients for 9 month of treatment. Thus this, project was effectively achieved this year with successful results.
|
